CN112760366A - Cerebral arterial thrombosis screening kit and preparation method thereof - Google Patents
Cerebral arterial thrombosis screening kit and preparation method thereof Download PDFInfo
- Publication number
- CN112760366A CN112760366A CN202110099950.4A CN202110099950A CN112760366A CN 112760366 A CN112760366 A CN 112760366A CN 202110099950 A CN202110099950 A CN 202110099950A CN 112760366 A CN112760366 A CN 112760366A
- Authority
- CN
- China
- Prior art keywords
- module
- kit
- pcr
- arterial thrombosis
- cerebral arterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010008092 Cerebral artery thrombosis Diseases 0.000 title claims abstract description 61
- 238000012216 screening Methods 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 238000012163 sequencing technique Methods 0.000 claims abstract description 52
- 210000004369 blood Anatomy 0.000 claims abstract description 50
- 239000008280 blood Substances 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000000746 purification Methods 0.000 claims abstract description 32
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 238000012408 PCR amplification Methods 0.000 claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 238000007731 hot pressing Methods 0.000 claims description 44
- 210000002966 serum Anatomy 0.000 claims description 43
- 238000000926 separation method Methods 0.000 claims description 25
- 239000002131 composite material Substances 0.000 claims description 22
- 238000004458 analytical method Methods 0.000 claims description 14
- 238000007400 DNA extraction Methods 0.000 claims description 13
- 239000003292 glue Substances 0.000 claims description 13
- 108091007422 miR-98 Proteins 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 9
- 238000003825 pressing Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 4
- 102000008946 Fibrinogen Human genes 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000010241 blood sampling Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 abstract description 61
- 238000013461 design Methods 0.000 abstract description 2
- 239000003550 marker Substances 0.000 abstract description 2
- 238000011160 research Methods 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of preparation of kits, and discloses a cerebral arterial thrombosis screening kit and a preparation method thereof, wherein the cerebral arterial thrombosis screening kit comprises a kit shell, a PCR (polymerase chain reaction) component and a product specification; the kit shell comprises an upper shell and a lower shell; the PCR assembly comprises a PCR reaction assembly, a PCR product purification assembly and a PCR sequencing assembly. The invention establishes the method for PCR amplification, purification and sequencing, can realize accurate acquisition of the cerebral arterial thrombosis marker, has simpler and more convenient scheme for PCR detection, can be realized only by blood treatment, reaction of the kit and sequencing after the reaction, and is more convenient and faster than the existing laboratory PCR amplification method. The kit provided by the invention is reasonable in design, can be used for predicting the risk of cerebral arterial thrombosis, realizing screening of cerebral arterial thrombosis and reducing the screening cost.
Description
Technical Field
The invention belongs to the technical field of preparation of kits, and particularly relates to a cerebral arterial thrombosis screening kit and a preparation method thereof.
Background
At present: according to the published data of the World Health Organization (WHO), cerebral apoplexy is one of the major diseases threatening the health of human beings globally, and is the third most fatal disease which is the first disability at present and is second to cancer and cardiovascular diseases. Epidemiology shows that the onset of stroke is younger and more increased year by year. The cerebral apoplexy is mainly divided into ischemic stroke and hemorrhagic stroke according to different causes, wherein the ischemic stroke accounts for 87 percent. Research reveals that the main pathological mechanisms affecting the occurrence and development of stroke include energy metabolism disorder, excessive depolarization of neurons, excitotoxic injury, imbalance of ion homeostasis, inflammation and immune disorder, apoptosis, autophagy and the like. The control of stroke fatality rate and improvement of life quality are problems to be solved urgently in current medical research. Currently, only tissue type fibrinogen activator (tPA) approved by FDA in the united states for treating stroke greatly limits its clinical wide application due to its strict treatment time window and complications such as easy induction of cerebral hemorrhage, and the development of drugs for stroke is still far from its task. With the progress of genetic engineering research, scientists have shown a great interest in developing drugs by genetic engineering. However, the existing method for screening cerebral arterial thrombosis is complex to operate, and a kit capable of realizing cerebral arterial thrombosis screening is not available.
Through the above analysis, the problems and defects of the prior art are as follows: at present, the method for screening the cerebral arterial thrombosis is complex to operate, and a kit capable of realizing the cerebral arterial thrombosis screening is not available temporarily.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a cerebral arterial thrombosis screening kit and a preparation method thereof.
The invention is realized in such a way, and an application method of the cerebral arterial thrombosis screening kit comprises the following steps:
step one, preparing a cerebral arterial thrombosis screening kit through a kit preparation module; collecting venous blood of a patient by a blood collecting module by using a blood collecting program; separating the serum in the collected venous blood by a serum separation module by using a serum separation program;
the preparation of the cerebral arterial thrombosis screening kit through the kit preparation module comprises the following steps:
(1.1) flatly placing the lower shell on a horizontal plane, performing spot coating on the bottom end in the lower shell by using fixing glue, sticking four corners of the bottom plate on the lower shell, extruding bubbles between the four corners of the bottom plate and the lower shell, and keeping the surface of the bottom plate smooth;
(1.2) connecting the water absorbing layer and the PCR reaction assembly from bottom to top to obtain a composite gasket for detection; cutting the composite gasket for detection, and covering the cut composite gasket on the bottom plate;
(1.3) carrying out hot pressing on the bottom plate and the composite gasket by using a hot pressing process, and completely fusing the edge of the composite gasket with the bottom plate;
(1.4) dividing a reaction detection area and a sample dripping area and respectively marking the divided two areas; the reaction detection area and the sample dripping area on the upper shell correspond to the reaction detection area and the sample dripping area defined in the lower shell;
(1.5) after deployment is finished, smearing the joint of the upper shell and the lower shell by using sealing glue, and solidifying the glue to obtain the cerebral arterial thrombosis screening kit;
extracting DNA in the separated serum by using a DNA extraction program through a DNA extraction module; dripping the extracted DNA into a sample dripping area of the kit;
performing PCR amplification by using the prepared kit through a PCR amplification module to obtain a kit after the reaction is finished;
transferring the kit to a laboratory, performing PCR purification, and performing PCR sequencing by using a PCR sequencing program through a PCR sequencing module;
analyzing the sequencing result by using a sequencing result analysis program through a sequencing result analysis module to obtain the expression level of miR-98;
and sixthly, prompting the risk of cerebral arterial thrombosis by using a risk prompting module and a risk prompting program when the expression level of miR-98 is lower than a threshold value.
Further, in the step (1.3), the hot-pressing of the base plate and the composite gasket by using a hot-pressing process includes:
1) setting a hot pressing mode of a hot press as zone hot pressing, and setting a hot pressing mode as zone outline hot pressing;
2) setting the outline of the area to be a rectangle, and determining the length and width specifications of the rectangle according to the specification of the composite gasket;
3) starting the hot press to carry out pre-hot pressing;
4) carrying out hot pressing treatment after preheating and pressing are finished, standing and cooling;
5) and checking the cooled gasket, checking the compactness of the hot-pressing part, and carrying out hot pressing again if the compactness is poor.
Further, the temperature of the pre-hot pressing is 80-85 ℃, and the time of the pre-hot pressing is 2-5 s.
Further, the hot pressing temperature is 110-130 ℃, and the preheating pressing time is 3-6 s.
Further, use and seal the glue and carry out the embrocation of going up casing and lower casing junction, glue solidifies and still needs to carry out after obtaining the cerebral arterial thrombosis screening kit:
and (5) coating the surface of the obtained cerebral arterial thrombosis screening kit, and putting the coated membrane and a product specification into a packaging box.
Further, in the first step, the separation of the serum in the collected venous blood by the serum separation module using the serum separation procedure includes:
step I, placing collected venous blood in a blood collection tube, and standing for 10-25 min at constant temperature;
step II, setting the centrifugal rotation speed to be 800-900 r/min, and centrifuging the venous blood after standing;
step III, after the centrifugation is finished, placing the blood collection tube in water bath at 37 ℃ for standing;
IV, performing fibrinogen stripping on the substances in the blood sampling tube;
and step V, carrying out precipitation.
Further, in step four, the PCR purification comprises: a PCR purification system is constructed in the kit, and the reaction conditions are that the reaction is carried out for 20min at 37 ℃ and 20min at 68 ℃.
Further, in the fourth step, the PCR purification system has a total volume of 40ul, and comprises 35ul of PCR product and 2.0ul of SAP enzyme per ul of 1U; 10U/ul ExoI enzyme 0.5 ul; dd H2O 2.5ul。
The invention also aims to provide a cerebral arterial thrombosis screening kit applying the application method of the cerebral arterial thrombosis screening kit, wherein the cerebral arterial thrombosis screening kit comprises a kit shell, a PCR (polymerase chain reaction) component and a product specification; the kit shell comprises an upper shell and a lower shell; the PCR assembly comprises a PCR reaction assembly, a PCR product purification assembly and a PCR sequencing assembly.
Another object of the present invention is to provide an application system of a cerebral arterial thrombosis screening kit for implementing the application method of the cerebral arterial thrombosis screening kit, where the cerebral arterial thrombosis screening kit application system includes:
the kit comprises a kit preparation module, a blood collection module, a serum separation module, a central control module, a DNA extraction module, a PCR amplification module, a PCR purification module, a PCR sequencing module, a sequencing result analysis module and a risk prompt module;
the kit preparation module is connected with the central control module and is used for preparing the cerebral arterial thrombosis screening kit;
the blood collection module is connected with the central control module and is used for collecting venous blood of the patient through a blood collection program;
the serum separation module is connected with the central control module and is used for separating the serum in the collected venous blood through a serum separation program;
the central control module is connected with the kit preparation module, the blood collection module, the serum separation module, the DNA extraction module, the PCR amplification module, the PCR purification module, the PCR sequencing module, the sequencing result analysis module and the risk prompt module and is used for controlling each module to normally operate through the main control computer;
the DNA extraction module is connected with the central control module and is used for extracting DNA in the separated serum through a DNA extraction program;
the PCR amplification module is connected with the central control module and is used for carrying out PCR amplification by using the prepared kit;
the PCR purification module is connected with the central control module and is used for carrying out PCR purification through a PCR purification program;
the PCR sequencing module is connected with the central control module and is used for carrying out PCR sequencing through a PCR sequencing program;
the sequencing result analysis module is connected with the central control module and is used for analyzing the sequencing result through a sequencing result analysis program to obtain the expression level of miR-98;
and the risk prompting module is connected with the central control module and used for prompting the risk of cerebral arterial thrombosis when the expression level of miR-98 is lower than a threshold value through a risk prompting program.
By combining all the technical schemes, the invention has the advantages and positive effects that: the invention establishes the method for PCR amplification, purification and sequencing, can realize accurate acquisition of the cerebral arterial thrombosis marker, has simpler and more convenient scheme for PCR detection, can be realized only by blood treatment, reaction of the kit and sequencing after the reaction, and is more convenient and faster than the existing laboratory PCR amplification method. The kit provided by the invention is reasonable in design, can be used for predicting the risk of cerebral arterial thrombosis, realizing screening of cerebral arterial thrombosis and reducing the screening cost.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings needed to be used in the embodiments of the present application will be briefly described below, and it is obvious that the drawings described below are only some embodiments of the present application, and it is obvious for those skilled in the art that other drawings can be obtained from the drawings without creative efforts.
Fig. 1 is a flowchart of an application method of the cerebral arterial thrombosis screening kit according to the embodiment of the present invention.
Fig. 2 is a flowchart of a method for preparing a cerebral arterial thrombosis screening kit through a kit preparation module according to an embodiment of the present invention.
Fig. 3 is a flowchart illustrating a hot pressing process of a base plate and a composite gasket according to an embodiment of the present invention.
Fig. 4 is a flow chart of the separation of the serum in the venous blood collected by the serum separation module using the serum separation procedure according to the embodiment of the present invention.
Fig. 5 is a structural block diagram of an application system of the ischemic stroke screening kit according to the embodiment of the present invention.
In fig. 5: 1. a kit preparation module; 2. a blood collection module; 3. a serum separation module; 4. a central control module; 5. a DNA extraction module; 6. a PCR amplification module; 7. a PCR purification module; 8. a PCR sequencing module; 9. a sequencing result analysis module; 10. and a risk prompt module.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Aiming at the problems in the prior art, the invention provides a cerebral arterial thrombosis screening kit and a preparation method thereof, and the invention is described in detail below with reference to the accompanying drawings.
As shown in fig. 1, an application method of the cerebral arterial thrombosis screening kit provided by the embodiment of the present invention includes the following steps:
s101, preparing a cerebral arterial thrombosis screening kit through a kit preparation module; collecting venous blood of a patient by a blood collecting module by using a blood collecting program; separating the serum in the collected venous blood by a serum separation module by using a serum separation program;
s102, extracting DNA in the separated serum by using a DNA extraction program through a DNA extraction module; dripping the extracted DNA into a sample dripping area of the kit;
s103, carrying out PCR amplification by using the prepared kit through a PCR amplification module to obtain a kit after the reaction is finished;
s104, transferring the kit to a laboratory, performing PCR purification, and performing PCR sequencing by using a PCR sequencing program through a PCR sequencing module;
s105, analyzing the sequencing result by using a sequencing result analysis program through a sequencing result analysis module to obtain the expression level of miR-98;
and S106, prompting the risk of cerebral arterial thrombosis by using a risk prompting module and a risk prompting program when the expression level of miR-98 is lower than a threshold value.
As shown in fig. 2, in step S101, the preparation of the kit for screening cerebral arterial thrombosis through the kit preparation module according to the embodiment of the present invention includes the following steps:
s201, horizontally placing a lower shell on a horizontal plane, performing spot coating on the bottom end inside the lower shell by using fixing glue, adhering four corners of a bottom plate on the lower shell, extruding bubbles between the four corners of the bottom plate and the lower shell, and keeping the surface of the bottom plate smooth;
s202, connecting the water absorbing layer and the PCR reaction assembly from bottom to top to obtain a composite gasket for detection; cutting the composite gasket for detection, and covering the cut composite gasket on the bottom plate;
s203, carrying out hot pressing on the bottom plate and the composite gasket by using a hot pressing process, and completely fusing the edge of the composite gasket with the bottom plate;
s204, dividing a reaction detection area and a sample dripping area, and respectively marking the divided two areas; the reaction detection area and the sample dripping area on the upper shell correspond to the reaction detection area and the sample dripping area defined in the lower shell;
s205, after deployment is finished, smearing the joint of the upper shell and the lower shell by using closed glue, and solidifying the glue to obtain the cerebral arterial thrombosis screening kit;
and S206, coating a film on the surface of the obtained cerebral arterial thrombosis screening kit, and putting the film and the product specification into a packaging box.
As shown in fig. 3, in step S203, the hot pressing of the bottom plate and the composite gasket by using the hot pressing process provided by the embodiment of the present invention includes:
s301, setting a hot pressing mode of a hot press as zone hot pressing, and setting a hot pressing mode as zone outline hot pressing;
s302, setting the outline of the area to be a rectangle, wherein the length and width specifications of the rectangle are determined according to the specification of the composite gasket;
s303, starting a hot press to carry out pre-hot pressing;
s304, carrying out hot pressing treatment after preheating and pressing are finished, and standing and cooling;
s305, checking the cooled gasket, checking the compactness of the hot-pressing part, and carrying out hot pressing again if the compactness is poor.
The temperature of the pre-hot pressing provided by the embodiment of the invention is 80-85 ℃, and the time of the pre-hot pressing is 2-5 s.
The hot pressing temperature provided by the embodiment of the invention is 110-130 ℃, and the preheating pressing time is 3-6 s.
As shown in fig. 4, in step S101, the separation of serum in venous blood collected by a serum separation module using a serum separation procedure according to an embodiment of the present invention includes:
s401, placing collected venous blood in a blood collection tube, and standing for 10-25 min at constant temperature;
s402, setting the centrifugal rotating speed to be 800-900 r/min, and centrifuging the venous blood after standing;
s403, after the centrifugation is finished, placing the blood collection tube in water bath at 37 ℃ for standing;
s404, performing fibrinogen stripping on the substance in the blood collection tube;
s405, carrying out precipitation.
In step S304, the PCR purification provided by the embodiment of the present invention includes: a PCR purification system is constructed in the kit, and the reaction conditions are that the reaction is carried out for 20min at 37 ℃ and 20min at 68 ℃.
In step S304, the total volume of the PCR purification system provided by the embodiment of the invention is 40ul, and the PCR purification system comprises 35ul of PCR product and 2.0ul of SAP enzyme per ul; 10U/ul ExoI enzyme 0.5 ul; dd H2O 2.5ul。
The cerebral arterial thrombosis screening kit provided by the embodiment of the invention comprises a kit shell, a PCR (polymerase chain reaction) component and a product specification; the kit shell comprises an upper shell and a lower shell; the PCR assembly comprises a PCR reaction assembly, a PCR product purification assembly and a PCR sequencing assembly.
As shown in fig. 5, an application system of the cerebral arterial thrombosis screening kit provided by the embodiment of the present invention includes:
the kit comprises a kit preparation module 1, a blood collection module 2, a serum separation module 3, a central control module 4, a DNA extraction module 5, a PCR amplification module 6, a PCR purification module 7, a PCR sequencing module 8, a sequencing result analysis module 9 and a risk prompt module 10;
the kit preparation module 1 is connected with the central control module and is used for preparing the cerebral arterial thrombosis screening kit;
the blood collection module 2 is connected with the central control module 4 and is used for collecting venous blood of a patient through a blood collection program;
the serum separation module 3 is connected with the central control module 4 and is used for separating the serum in the collected venous blood through a serum separation program;
the central control module 4 is connected with the kit preparation module 1, the blood collection module 2, the serum separation module 3, the DNA extraction module 5, the PCR amplification module 6, the PCR purification module 7, the PCR sequencing module 8, the sequencing result analysis module 9 and the risk prompt module 10 and is used for controlling the normal operation of each module through a main control computer;
a DNA extraction module 5 connected with the central control module 4 and used for extracting DNA in the separated serum through a DNA extraction program;
the PCR amplification module 6 is connected with the central control module 4 and is used for carrying out PCR amplification by using the prepared kit;
the PCR purification module 7 is connected with the central control module 4 and is used for carrying out PCR purification through a PCR purification program;
the PCR sequencing module 8 is connected with the central control module 4 and is used for carrying out PCR sequencing through a PCR sequencing program;
the sequencing result analysis module 9 is connected with the central control module 4 and is used for analyzing the sequencing result through a sequencing result analysis program to obtain the expression level of miR-98;
and the risk prompting module 10 is connected with the central control module 4 and is used for prompting the risk of cerebral arterial thrombosis through a risk prompting program when the expression level of miR-98 is lower than a threshold value.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention, and the scope of the present invention is not limited thereto, and any modification, equivalent replacement, and improvement made by those skilled in the art within the technical scope of the present invention disclosed herein, which is within the spirit and principle of the present invention, should be covered by the present invention.
Claims (10)
1. An application method of a cerebral arterial thrombosis screening kit is characterized by comprising the following steps:
step one, preparing a cerebral arterial thrombosis screening kit through a kit preparation module; collecting venous blood of a patient by a blood collecting module by using a blood collecting program; separating the serum in the collected venous blood by a serum separation module by using a serum separation program;
the preparation of the cerebral arterial thrombosis screening kit through the kit preparation module comprises the following steps:
(1.1) flatly placing the lower shell on a horizontal plane, performing spot coating on the bottom end in the lower shell by using fixing glue, sticking four corners of the bottom plate on the lower shell, extruding bubbles between the four corners of the bottom plate and the lower shell, and keeping the surface of the bottom plate smooth;
(1.2) connecting the water absorbing layer and the PCR reaction assembly from bottom to top to obtain a composite gasket for detection; cutting the composite gasket for detection, and covering the cut composite gasket on the bottom plate;
(1.3) carrying out hot pressing on the bottom plate and the composite gasket by using a hot pressing process, and completely fusing the edge of the composite gasket with the bottom plate;
(1.4) dividing a reaction detection area and a sample dripping area and respectively marking the divided two areas; the reaction detection area and the sample dripping area on the upper shell correspond to the reaction detection area and the sample dripping area defined in the lower shell;
(1.5) after deployment is finished, smearing the joint of the upper shell and the lower shell by using sealing glue, and solidifying the glue to obtain the cerebral arterial thrombosis screening kit;
extracting DNA in the separated serum by using a DNA extraction program through a DNA extraction module; dripping the extracted DNA into a sample dripping area of the kit;
performing PCR amplification by using the prepared kit through a PCR amplification module to obtain a kit after the reaction is finished;
transferring the kit to a laboratory, performing PCR purification, and performing PCR sequencing by using a PCR sequencing program through a PCR sequencing module;
analyzing the sequencing result by using a sequencing result analysis program through a sequencing result analysis module to obtain the expression level of miR-98;
and sixthly, prompting the risk of cerebral arterial thrombosis by using a risk prompting module and a risk prompting program when the expression level of miR-98 is lower than a threshold value.
2. The application method of the cerebral arterial thrombosis screening kit as claimed in claim 1, wherein in step (1.3), the hot pressing of the bottom plate and the composite gasket by using a hot pressing process comprises:
1) setting a hot pressing mode of a hot press as zone hot pressing, and setting a hot pressing mode as zone outline hot pressing;
2) setting the outline of the area to be a rectangle, and determining the length and width specifications of the rectangle according to the specification of the composite gasket;
3) starting the hot press to carry out pre-hot pressing;
4) carrying out hot pressing treatment after preheating and pressing are finished, standing and cooling;
5) and checking the cooled gasket, checking the compactness of the hot-pressing part, and carrying out hot pressing again if the compactness is poor.
3. The application method of the cerebral arterial thrombosis screening kit as claimed in claim 2, wherein the pre-heating pressing temperature is 80-85 ℃ and the pre-heating pressing time is 2-5 s.
4. The application method of the cerebral arterial thrombosis screening kit as claimed in claim 2, wherein the hot pressing temperature is 110-130 ℃, and the preheating pressing time is 3-6 s.
5. The application method of the stroke ischemic screening kit as claimed in claim 1, wherein the joint between the upper shell and the lower shell is coated with the sealing glue, and after the glue is solidified to obtain the stroke ischemic screening kit, the steps of:
and (5) coating the surface of the obtained cerebral arterial thrombosis screening kit, and putting the coated membrane and a product specification into a packaging box.
6. The method for applying the cerebral arterial thrombosis screening kit as claimed in claim 1, wherein in the first step, the separation of the serum in the collected venous blood by the serum separation module using the serum separation procedure comprises:
step I, placing collected venous blood in a blood collection tube, and standing for 10-25 min at constant temperature;
step II, setting the centrifugal rotation speed to be 800-900 r/min, and centrifuging the venous blood after standing;
step III, after the centrifugation is finished, placing the blood collection tube in water bath at 37 ℃ for standing;
IV, performing fibrinogen stripping on the substances in the blood sampling tube;
and step V, carrying out precipitation.
7. The method for applying the cerebral arterial thrombosis screening kit as claimed in claim 1, wherein in step four, the PCR purification comprises: a PCR purification system is constructed in the kit, and the reaction conditions are that the reaction is carried out for 20min at 37 ℃ and 20min at 68 ℃.
8. The application method of the cerebral arterial thrombosis screening kit as claimed in claim 1, wherein in the fourth step, the PCR purification system has a total volume of 40ul, and comprises 35ul of PCR product and 2.0ul of SAP enzyme per ul; 10U/ul ExoI enzyme 0.5 ul; dd H2O 2.5ul。
9. The cerebral arterial thrombosis screening kit applying the application method of the cerebral arterial thrombosis screening kit as claimed in claims 11 to 8, wherein the cerebral arterial thrombosis screening kit comprises a kit shell, a PCR component and a product instruction book; the kit shell comprises an upper shell and a lower shell; the PCR assembly comprises a PCR reaction assembly, a PCR product purification assembly and a PCR sequencing assembly.
10. An ischemic stroke screening kit application system for implementing the method for applying the ischemic stroke screening kit as claimed in claims 1 to 8, wherein the ischemic stroke screening kit application system comprises:
the kit comprises a kit preparation module, a blood collection module, a serum separation module, a central control module, a DNA extraction module, a PCR amplification module, a PCR purification module, a PCR sequencing module, a sequencing result analysis module and a risk prompt module;
the kit preparation module is connected with the central control module and is used for preparing the cerebral arterial thrombosis screening kit;
the blood collection module is connected with the central control module and is used for collecting venous blood of the patient through a blood collection program;
the serum separation module is connected with the central control module and is used for separating the serum in the collected venous blood through a serum separation program;
the central control module is connected with the kit preparation module, the blood collection module, the serum separation module, the DNA extraction module, the PCR amplification module, the PCR purification module, the PCR sequencing module, the sequencing result analysis module and the risk prompt module and is used for controlling each module to normally operate through the main control computer;
the DNA extraction module is connected with the central control module and is used for extracting DNA in the separated serum through a DNA extraction program;
the PCR amplification module is connected with the central control module and is used for carrying out PCR amplification by using the prepared kit;
the PCR purification module is connected with the central control module and is used for carrying out PCR purification through a PCR purification program;
the PCR sequencing module is connected with the central control module and is used for carrying out PCR sequencing through a PCR sequencing program;
the sequencing result analysis module is connected with the central control module and is used for analyzing the sequencing result through a sequencing result analysis program to obtain the expression level of miR-98;
and the risk prompting module is connected with the central control module and used for prompting the risk of cerebral arterial thrombosis when the expression level of miR-98 is lower than a threshold value through a risk prompting program.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110099950.4A CN112760366A (en) | 2021-01-25 | 2021-01-25 | Cerebral arterial thrombosis screening kit and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110099950.4A CN112760366A (en) | 2021-01-25 | 2021-01-25 | Cerebral arterial thrombosis screening kit and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112760366A true CN112760366A (en) | 2021-05-07 |
Family
ID=75707313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110099950.4A Pending CN112760366A (en) | 2021-01-25 | 2021-01-25 | Cerebral arterial thrombosis screening kit and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112760366A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150276763A1 (en) * | 2012-10-24 | 2015-10-01 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Biomarkers for the prognosis of ischemic stroke |
| CN105648073A (en) * | 2016-02-26 | 2016-06-08 | 南京医科大学 | Ischemic stroke screening kit and application thereof |
| US20200386773A1 (en) * | 2017-12-25 | 2020-12-10 | Xuanwu Hospital Of Capital Medical University | Antibody for detecting early damage to blood-brain barrier in ischemic stroke and use thereof |
-
2021
- 2021-01-25 CN CN202110099950.4A patent/CN112760366A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150276763A1 (en) * | 2012-10-24 | 2015-10-01 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Biomarkers for the prognosis of ischemic stroke |
| CN105648073A (en) * | 2016-02-26 | 2016-06-08 | 南京医科大学 | Ischemic stroke screening kit and application thereof |
| US20200386773A1 (en) * | 2017-12-25 | 2020-12-10 | Xuanwu Hospital Of Capital Medical University | Antibody for detecting early damage to blood-brain barrier in ischemic stroke and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111733056B (en) | Micro-fluidic chip integrating circulating tumor cell separation and single-cell immunoblotting | |
| Chou et al. | The utilization of optically-induced-dielectrophoresis (ODEP)-based virtual cell filters in a microfluidic system for continuous isolation and purification of circulating tumour cells (CTCs) based on their size characteristics | |
| Zou et al. | Advances in isolation and detection of circulating tumor cells based on microfluidics | |
| EP1693109A1 (en) | Container for separating tumor cells | |
| Hu et al. | Detection of circulating tumor cells: Advances and critical concerns | |
| CN108896364A (en) | For feed, livestock fecaluria, tissue sample pre-treatment centrifugal ultrafiltration unit | |
| JP2018508194A (en) | Microfluidics-based fetal cell detection and isolation for non-invasive prenatal testing | |
| CN105950739A (en) | Probe for detecting circulating tumor DNA (Deoxyribonucleic Acid) of human breast cancer and application of probe | |
| Ferrara et al. | Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics | |
| CN112760366A (en) | Cerebral arterial thrombosis screening kit and preparation method thereof | |
| TW201738381A (en) | Method and apparatus for purifying and separating circulating tumor cells in blood by using non-contact and automatic identification by which highly purified circulating tumor cells are collected with high efficiency | |
| Chavez‐Pineda et al. | Microfluidic systems for the analysis of blood‐derived molecular biomarkers | |
| CN114317400A (en) | Exosome separation purification detection method and device | |
| CN106480017A (en) | Extract the test kit of circulating tumor cell DNA and tumor dissociative DNA simultaneously | |
| CN107533046A (en) | Fluid separator for molecule diagnosis by bed | |
| CN107988042A (en) | A kind of circulating tumor cell separator and its detection method | |
| CN101173909B (en) | Serum protein electrophoresis gelose gel plate and production method thereof | |
| US20230358706A1 (en) | Devices and methods for urine sample analysis | |
| Cheng et al. | 3D spiral channels combined with flexible micro-sieve for high-throughput rare tumor cell enrichment and assay from clinical pleural effusion samples | |
| JPS58198759A (en) | Blood glucose meter | |
| Barh et al. | Single-Cell Omics: Volume 2: Applications in Biomedicine and Agriculture | |
| CN113337597B (en) | Detection kit for pregnancy vitamin A deficiency risk assessment and application method | |
| CN211865100U (en) | Micro sample separation experiment table | |
| Grigoriadis et al. | A novel combined methodology for isolation and detection of circulating tumor cells based on flow cytometry and cellular filtration technologies | |
| CN206057343U (en) | A kind of low abundance hormone test device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210507 |